[go: up one dir, main page]

MA45675B1 - Procédés et compositions pour le traitement du cancer - Google Patents

Procédés et compositions pour le traitement du cancer

Info

Publication number
MA45675B1
MA45675B1 MA45675A MA45675A MA45675B1 MA 45675 B1 MA45675 B1 MA 45675B1 MA 45675 A MA45675 A MA 45675A MA 45675 A MA45675 A MA 45675A MA 45675 B1 MA45675 B1 MA 45675B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
compositions
methods
polypeptide
Prior art date
Application number
MA45675A
Other languages
English (en)
Other versions
MA45675A (fr
Inventor
Laura Soucek
Toni JAUSET GONZÁLEZ
Marie-Eve Beaulieu
Original Assignee
Institució Catalana de Recerca I EstudisAvançats
Fundació Privada Institut D'investigacióoncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana de Recerca I EstudisAvançats, Fundació Privada Institut D'investigacióoncològica De Vall Hebron filed Critical Institució Catalana de Recerca I EstudisAvançats
Publication of MA45675A publication Critical patent/MA45675A/fr
Publication of MA45675B1 publication Critical patent/MA45675B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un polypeptide comprenant ou constitué du polypeptide de SEQ ID NO: 1 dans laquelle le résidu X à la position 89 de la SEQ ID NO: 1 n'est pas une cystéine, ou un variant fonctionnellement équivalent dudit polypeptide dans lequel le résidu X à la position 89 de SEQ ID NO: 1 n'est pas une cystéine et leur utilisation en médecine, en particulier dans la prévention et/ou le traitement du cancer.
MA45675A 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer MA45675B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382339.6A EP3269734A1 (fr) 2016-07-15 2016-07-15 Procédés et compositions pour le traitement du cancer
EP17746413.8A EP3484913B1 (fr) 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer
PCT/EP2017/067998 WO2018011433A1 (fr) 2016-07-15 2017-07-17 Méthodes et compositions permettant le traitement du cancer

Publications (2)

Publication Number Publication Date
MA45675A MA45675A (fr) 2021-04-21
MA45675B1 true MA45675B1 (fr) 2024-07-31

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45675A MA45675B1 (fr) 2016-07-15 2017-07-17 Procédés et compositions pour le traitement du cancer

Country Status (21)

Country Link
US (1) US11427621B2 (fr)
EP (2) EP3269734A1 (fr)
JP (1) JP7090593B2 (fr)
KR (1) KR102232500B1 (fr)
CN (1) CN109563151B (fr)
AU (1) AU2017295071B2 (fr)
BR (1) BR112019000732A2 (fr)
EA (1) EA201990298A1 (fr)
ES (1) ES2985967T3 (fr)
HR (1) HRP20241153T1 (fr)
HU (1) HUE067973T2 (fr)
IL (1) IL264176B2 (fr)
MA (1) MA45675B1 (fr)
MD (1) MD3484913T2 (fr)
MX (1) MX2019000346A (fr)
PL (1) PL3484913T3 (fr)
RS (1) RS65983B1 (fr)
SG (1) SG11201900021PA (fr)
SM (1) SMT202400360T1 (fr)
WO (1) WO2018011433A1 (fr)
ZA (1) ZA201900960B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (fr) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Procédés et compositions pour le traitement du cancer
WO2020041297A1 (fr) * 2018-08-20 2020-02-27 Helix Nanotechnologies, Inc. Méthodes et compositions pour l'expression de l'arn d'inhibiteurs de myc
US20220152179A1 (en) * 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
WO2021208787A1 (fr) * 2020-04-15 2021-10-21 徐荣臻 Polypeptide cible utilisé pour le criblage de médicaments et procédé de criblage associé
EP4361633A1 (fr) 2022-10-25 2024-05-01 Peptomyc, S.L. Procédé de prédiction de la réponse à un traitement du cancer
EP4446742A1 (fr) 2023-04-14 2024-10-16 Peptomyc, S.L. Procédé d'évaluation ou de surveillance de la réponse à un traitement du cancer
EP4473974A1 (fr) * 2023-06-07 2024-12-11 Peptomyc, S.L. Polythérapie avec omomyc et des inhibiteurs de kras pour le traitement du cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (fr) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Méthode de préparation de vésicules lipidiques par traitement aux ultra-sons, utilisation de ce procédé et l'appareillage ainsi utilisé
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
CA2140343A1 (fr) 1992-07-17 1994-02-03 Sean M. Sullivan Methode et reactif pour le traitement de maladies d'animaux
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5942433A (en) * 1995-07-31 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2317549C (fr) 1998-01-05 2006-04-11 University Of Washington Composition pour l'amelioration du transport par l'utilisation de membranes contenant des lipides et utilisation connexe
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
US9241920B2 (en) 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (fr) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Procédé et compositions de traitement du cancer
EP3269734A1 (fr) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Procédés et compositions pour le traitement du cancer

Also Published As

Publication number Publication date
EP3484913B1 (fr) 2024-07-03
PL3484913T3 (pl) 2025-01-07
JP2019525753A (ja) 2019-09-12
MD3484913T2 (ro) 2024-10-31
EP3484913A1 (fr) 2019-05-22
CA3029781A1 (fr) 2018-01-18
HUE067973T2 (hu) 2024-11-28
US20200247857A1 (en) 2020-08-06
SMT202400360T1 (it) 2024-11-15
CN109563151A (zh) 2019-04-02
US11427621B2 (en) 2022-08-30
HRP20241153T1 (hr) 2024-11-22
IL264176A (en) 2019-02-28
RS65983B1 (sr) 2024-10-31
MX2019000346A (es) 2019-04-01
EP3269734A1 (fr) 2018-01-17
KR20190032427A (ko) 2019-03-27
IL264176B2 (en) 2023-07-01
MA45675A (fr) 2021-04-21
EA201990298A1 (ru) 2019-06-28
AU2017295071B2 (en) 2022-06-09
ZA201900960B (en) 2020-05-27
IL264176B1 (en) 2023-03-01
WO2018011433A1 (fr) 2018-01-18
EP3484913C0 (fr) 2024-07-03
AU2017295071A1 (en) 2019-01-31
KR102232500B1 (ko) 2021-03-26
JP7090593B2 (ja) 2022-06-24
SG11201900021PA (en) 2019-01-30
BR112019000732A2 (pt) 2019-07-30
ES2985967T3 (es) 2024-11-08
CN109563151B (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
MA45675B1 (fr) Procédés et compositions pour le traitement du cancer
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
ZA201803396B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
MA41547B1 (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
GEP20257840B (en) Tyk2 pseudokinase ligands
HK1253734A1 (zh) 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
NZ739392A (en) Methods for treating hepcidin-mediated disorders
MX378431B (es) Uso terapèutico de proteìnas morfogenèticas òseas.
PH12018502465A1 (en) Mic-1 compounds and use thereof
MA39342B2 (fr) Anticorps il -21
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2020007628A (es) Composiciones y metodos de uso.
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
EA202090184A2 (ru) Пептидные композиции и способы использования
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
JP2017505772A5 (fr)
PH12021550122A1 (en) Solubilized apyrases, methods and use
JOP20220110A1 (ar) ناهضات مستقبل npy2
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
EP3530278A4 (fr) Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés